ATE144898T1 - Behandlung neurodegenerativer krankheiten - Google Patents
Behandlung neurodegenerativer krankheitenInfo
- Publication number
- ATE144898T1 ATE144898T1 AT93302729T AT93302729T ATE144898T1 AT E144898 T1 ATE144898 T1 AT E144898T1 AT 93302729 T AT93302729 T AT 93302729T AT 93302729 T AT93302729 T AT 93302729T AT E144898 T1 ATE144898 T1 AT E144898T1
- Authority
- AT
- Austria
- Prior art keywords
- neurodegenerative diseases
- compounds
- treatment
- unsaturated
- certain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86659792A | 1992-04-10 | 1992-04-10 | |
US08/023,940 US5276043A (en) | 1992-04-10 | 1993-03-12 | Method for treatment of neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE144898T1 true ATE144898T1 (de) | 1996-11-15 |
Family
ID=26697824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT93302729T ATE144898T1 (de) | 1992-04-10 | 1993-04-07 | Behandlung neurodegenerativer krankheiten |
Country Status (5)
Country | Link |
---|---|
US (1) | US5276043A (de) |
EP (1) | EP0567251B1 (de) |
JP (1) | JPH069397A (de) |
AT (1) | ATE144898T1 (de) |
DE (1) | DE69305776T2 (de) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0137003B1 (ko) | 1991-03-01 | 1998-04-25 | 카렌 에이. 홀브루크 | 신경계 퇴행성 질환치료용 니코틴 아날로그의 용도 |
US5977144A (en) * | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
US5510355A (en) * | 1994-09-06 | 1996-04-23 | Bencherif; Merouane | Depolarizing skeletal muscle relaxants |
US5594011A (en) * | 1994-11-10 | 1997-01-14 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5723477A (en) * | 1994-11-10 | 1998-03-03 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5705512A (en) * | 1994-11-10 | 1998-01-06 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5677459A (en) * | 1994-11-10 | 1997-10-14 | Sibia Neurosciences, Inc. | Methods for the preparation of modulators of acetylcholine receptors |
US5703100A (en) * | 1994-11-10 | 1997-12-30 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US6194581B1 (en) | 1995-04-07 | 2001-02-27 | Merck & Co., Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
US5691365A (en) * | 1995-07-18 | 1997-11-25 | University Of Kentucky Research Foundation | Nicotinic receptor antagonists in the treatment of neuropharmacological disorders |
US5794887A (en) | 1995-11-17 | 1998-08-18 | Komerath; Narayanan M. | Stagnation point vortex controller |
US5776957A (en) * | 1996-11-15 | 1998-07-07 | The University Of Kentucky Research Foundation | Nornicotine enantiomers for use as a treatment for dopamine related conditions and disease states |
EP1083913A4 (de) * | 1998-06-05 | 2004-03-17 | Regent Court Technologies | Monoaminoxidase (mao) inhibitoren und ihre verwendung . |
US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
US6432975B1 (en) | 1998-12-11 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
US6890935B2 (en) * | 1999-11-01 | 2005-05-10 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
US7070817B2 (en) * | 2002-06-26 | 2006-07-04 | Murali K Chada | Herbal composition for treating or alleviating vascular headaches, neurological conditions and neurodegenerative diseases |
WO2004103991A1 (fr) * | 2003-05-20 | 2004-12-02 | 'chemical Diversity Research Institute', Ltd. | Piperidines 2-substituees, bibliotheque focalisee et composition pharmaceutique |
SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
US8207346B2 (en) | 2010-03-23 | 2012-06-26 | Rock Creek Pharmaceuticals, Inc. | Methods of synthesizing anatabine |
CA2794097C (en) * | 2010-03-23 | 2016-08-09 | Rock Creek Pharmaceuticals, Inc. | Use of anatabine to treat inflammation and methods of synthesizing anatabine |
AU2012249487A1 (en) * | 2011-04-28 | 2013-11-07 | Rcp Development, Inc. | Methods of administering anatabine to treat Autism Spectrum Disorders and seizure disorders |
US20130048001A1 (en) * | 2011-08-29 | 2013-02-28 | Jonnie R. Williams | Anatabine-Enriched Tobacco Products |
AU2012302257A1 (en) * | 2011-08-29 | 2014-03-13 | Rcp Development, Inc. | Products for anti-inflammation support |
US10111948B2 (en) | 2014-04-25 | 2018-10-30 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
US10471052B2 (en) | 2015-02-19 | 2019-11-12 | Mymd Pharmaceuticals, Inc. | Method of treating addictions to opioids |
US11219620B2 (en) | 2015-03-31 | 2022-01-11 | MyMD Pharmaceuticals (Florida), Inc. | Methods of treating sarcopenia |
ES2958524T3 (es) * | 2015-03-31 | 2024-02-09 | Mymd Pharmaceuticals Inc | Isomiosmina para uso en el tratamiento de enfermedades autoinmunes |
WO2016161051A1 (en) * | 2015-03-31 | 2016-10-06 | Srq Patent Holdings, Llc | Skin care products containing isomyosmine |
US9724340B2 (en) | 2015-07-31 | 2017-08-08 | Attenua, Inc. | Antitussive compositions and methods |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3870794A (en) * | 1974-02-20 | 1975-03-11 | Foundation For Behavioral Rese | Treatment of certain emotional disorders with nicotine compounds |
HU179164B (en) * | 1979-12-14 | 1982-08-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing cycloalkyl-ethers of alkanolamines |
US4442292A (en) * | 1981-01-29 | 1984-04-10 | Philip Morris Incorporated | Optically active nicotine analogs and process for their preparation |
US4578394A (en) * | 1984-12-10 | 1986-03-25 | Hoechst-Roussel Pharmaceuticals Incorporated | Cholinergic function increasing 3-[N-(pyridyl) carbamoyl]-1,4-dihydropyridines |
US4965074A (en) * | 1985-03-05 | 1990-10-23 | Ciba-Geigy Corporation | Method of treating memory impairment |
US4765985A (en) * | 1985-03-05 | 1988-08-23 | Ciba-Geigy Corporation | Devices and methods for treating memory impairment |
US4863930A (en) * | 1986-12-19 | 1989-09-05 | Adhikary Parimal K | Use of substituted 5H-pyrido- and 5H-thiazolo(2',1':2,3)imidazo (4,5-b)indoles as cholinomimetic agents |
IE63906B1 (en) * | 1987-11-13 | 1995-06-14 | Novo Nordisk As | Azabicyclic compounds and their preparation and use |
IE62662B1 (en) * | 1989-01-06 | 1995-02-22 | Elan Corp Plc | Use of nicotine in the treatment of conditions susceptible to said treatment |
US5015741A (en) * | 1989-10-03 | 1991-05-14 | Philip Morris Incorporated | Nicotine analogs |
KR0137003B1 (ko) * | 1991-03-01 | 1998-04-25 | 카렌 에이. 홀브루크 | 신경계 퇴행성 질환치료용 니코틴 아날로그의 용도 |
US5187169A (en) * | 1992-04-10 | 1993-02-16 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
-
1993
- 1993-03-12 US US08/023,940 patent/US5276043A/en not_active Expired - Fee Related
- 1993-04-01 JP JP5096460A patent/JPH069397A/ja not_active Withdrawn
- 1993-04-07 AT AT93302729T patent/ATE144898T1/de not_active IP Right Cessation
- 1993-04-07 EP EP93302729A patent/EP0567251B1/de not_active Expired - Lifetime
- 1993-04-07 DE DE69305776T patent/DE69305776T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0567251A1 (de) | 1993-10-27 |
DE69305776D1 (de) | 1996-12-12 |
US5276043A (en) | 1994-01-04 |
DE69305776T2 (de) | 1997-05-15 |
JPH069397A (ja) | 1994-01-18 |
EP0567251B1 (de) | 1996-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE144898T1 (de) | Behandlung neurodegenerativer krankheiten | |
DE69733132D1 (de) | Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen | |
ATE93138T1 (de) | Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. | |
ATE197670T1 (de) | Parenterales busulfan zur behandlung von malignen krankheiten | |
DE69526937D1 (de) | Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen | |
NO961478D0 (no) | Levobupivacaine anvendelig for kontroll av kronisk smerte | |
ATE201992T1 (de) | Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen | |
DE69424777T2 (de) | 3,4-diarylchromane zur behandlung von dermatitis | |
DE69725879D1 (de) | VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN | |
ATE125704T1 (de) | Behandlung neurodegenerativer erkrankungen. | |
ATE180669T1 (de) | Verwendung von pregnanderivaten zur behandlung von tumoren | |
ATE266027T1 (de) | Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten | |
ATE239470T1 (de) | Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen | |
DE69304843D1 (de) | Methode zur Behandlung von Haarausfall | |
ATE252387T1 (de) | Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen | |
DE3582935D1 (de) | Mittel zur behandlung von erkrankungen der venen und des analbereichs. | |
DE69621786D1 (de) | Aminotetralinderivat zur behandlung von herzkreislauferkrankung | |
ATE293972T1 (de) | Behandlung von chronischen schmerzen | |
ATE302011T1 (de) | PONAZURIL ZUR BEHANDLUNG VON DURCH COCCIDIA NEUROLOGISCHEN UND ßABORTIGENICß VERURSACHTEN ERKRANKUNGEN | |
ATE204476T1 (de) | Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazi e zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem | |
DE69223455T2 (de) | WS7622A enthaltende prophylaktische/therapeutische Zusammensetzung zur Vorbeugung und Behandlung von verstreuter, intravaskulärer Koagulation, chronischer, infektiöser Atemwegskrankheiten oder chronischer Bronchitis | |
NO984196D0 (no) | Fremgangsmåte for behandling av stoffmisbruk | |
NO984198L (no) | FremgangsmÕte for behandling av aggresjon | |
DE69830811D1 (de) | Verwendung von Oxazolidinonderivaten zur Behandlung von Psoriasis | |
DE69133542D1 (de) | Katheter zur Behandlung von Prostaterkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |